Outcomes following iodine-125 brachytherapy in patients with Gleason 7, intermediate risk prostate cancer: A population-based cohort study

Radiotherapy and Oncology

Volumn 103, Issue 2, 2012, Pages 228-232

  Herbert, Christopher ^a   Morris, W James ^a   Keyes, Mira ^a   Hamm, Jeremy ^a   Lapointe, Vincent ^a   McKenzie, Michael ^a   Pickles, Thomas ^a   Spadinger, Ingrid ^a  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

Biochemical recurrence; Brachytherapy; Gleason 7; Prostate cancer

Indexed keywords

IODINE 125;

ADULT; AGED; ARTICLE; BRACHYTHERAPY; CANCER RISK; COHORT ANALYSIS; DOSIMETRY; FOLLOW UP; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; POPULATION RESEARCH; PRIORITY JOURNAL; PROSTATE CANCER;

AGED; AGED, 80 AND OVER; BRACHYTHERAPY; COHORT STUDIES; HUMANS; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; NEOPLASM GRADING; PROSTATIC NEOPLASMS; RADIOTHERAPY DOSAGE; TREATMENT OUTCOME;

EID: 84860433493     PISSN: 01678140     EISSN: 18790887     Source Type: Journal    
DOI: 10.1016/j.radonc.2012.01.006     Document Type: Article

References (22)

1. N.P. Munro, B. Al-Qaisieh, and P. Bownes Outcomes from Gleason 7, intermediate risk, localised prostate cancer treated with iodine-125 monotherapy over 10 years Radiother Oncol 96 2010 34 37
2. M.J. Burdick, C.A. Reddy, and J. Ulchaker Comparison of biochemical relapse-free survival between primary Gleason score 3 and primary Gleason score 4 for biopsy Gleason score 7 prostate cancer Int J Radiat Oncol Biol Phys 73 2009 1439 1445
3. G.S. Merrick, R.W. Galbreath, and W.M. Butler Primary Gleason pattern does not impact survival after permanent interstitial brachytherapy for Gleason 7 prostate cancer Cancer 110 2007 289 296
4. L. Potters, R. Purrazzella, and S. Brustein The prognostic significance of Gleason Grade in patients treated with permanent prostate brachytherapy Int J Radiat Oncol Biol Phys 56 2003 749 754
5. M.J. Zelefsky, D.A. Kuban, and L.B. Levy Multi-institutional analysis of long-term outcome for stages T1-T2 prostate cancer treated with permanent seed implantation Int J Radiat Oncol Biol Phys 67 2007 327 333
6. A.Y. Ho, R.J. Burri, J.A. Cesaretti, N.N. Stone, and R.G. Stock Radiation dose predicts for biochemical control in intermediate-risk prostate cancer patients treated with low-dose-rate brachytherapy Int J Radiat Oncol Biol Phys 75 2009 16 22
7. A.M. Henry, B. Al-Qaisieh, and K. Gould Outcomes following iodine-125 monotherapy for localized prostate cancer: the results of Leeds 10-year single-center brachytherapy experience Int J Radiat Oncol Biol Phys 76 2010 50 56
8. 125I brachytherapy Brachytherapy 1 2011 S48 S49
9. J.C. Blasko, T. Mate, J.E. Sylvester, P.D. Grimm, and W. Cavanagh Brachytherapy for carcinoma of the prostate: techniques, patient selection, and clinical outcomes Semin Radiat Oncol 12 2002 81 94
10. 125iodine transperineal brachytherapy for low- and intermediate-risk prostate cancer Int J Radiat Oncol Biol Phys 73 2009 1432 1438
11. C.W. Thomas, A. Kruk, C.E. McGahan, I. Spadinger, and W.J. Morris Prostate brachytherapy post-implant dosimetry: a comparison between higher and lower source density Radiother Oncol 83 2007 18 24
12. M. Roach III, G. Hanks, and H. Thames Jr. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference Int J Radiat Oncol Biol Phys 65 2006 965 974
13. J. Mohler, R.R. Bahnson, and B. Boston NCCN clinical practice guidelines in oncology: prostate cancer J Natl Compr Canc Netw 8 2010 162 200
14. S.J. Frank, P.D. Grimm, and J.E. Sylvester Interstitial implant alone or in combination with external beam radiation therapy for intermediate risk prostate cancer: a survey of practice patterns in the United States Brachytherapy 6 2007 2 8
15. J.M. Cosset, T. Flam, and N. Thiounn Selecting patients for permanent implant prostate brachytherapy: the experience of the Paris Institut Curie/Cochin Hospital/necker Hospital Group on 809 patients Int J Radiat Oncol Biol Phys 71 2008 1042 1048
16. M.W. Kattan, P.A. Fearn, S. Leibel, and L. Potters The definition of biochemical failure in patients treated with definitive radiotherapy Int J Radiat Oncol Biol Phys 48 2000 1469 1474
17. D. Ash, B. Al-Qaisieh, D. Bottomley, B. Carey, and J. Joseph The impact of hormone therapy on post-implant dosimetry and outcome following iodine-125 implant monotherapy for localised prostate cancer Radiother Oncol 75 2005 303 306
18. 125I brachytherapy for low- and intermediate risk prostate cancer Urology 73 2009 860 865
19. B.R. Prestidge, W.S. Bice, E.J. Kiefer, and J.J. Prete Timing of computed tomography-based postimplant assessment following permanent transperineal prostate brachytherapy Int J Radiat Oncol Biol Phys 40 1998 1111 1115
20. F.M. Waterman, N. Yue, B.W. Corn, and A. Dicker Edema associated with I-125 or Pd-103 prostate brachytherapy and its impact on post-implant dosimetry: an analysis based on serial CT acquisition Int J Radiat Oncol Biol Phys 41 1998 1069 1077
21. W.J. Morris, I. Spadinger, M. Keyes, M. McKenzie, and T. Pickles CT based dosimetry following low dose rate (LDR) prostate brachytherapy in 2787 consecutive cases over 11 years Int J Radiat Oncol Biol Phys 78 2010 S362
22. W.J. Morris, R. Halperin, and I. Spadinger Point: the relationship between post implant dose metrics and biochemical no evidence of disease following low dose rate prostate brachytherapy: Is there an elephant in the room? Brachytherapy 9 2010 289 292